Moderna Announces Significant Advancements in Vaccine Development Programs

Moderna, Inc. disclosed substantial progress in its vaccine development efforts, highlighting advancements across multiple programs into late-stage clinical trials. The company’s next-generation COVID-19 vaccine candidate successfully met Phase 3 endpoints, positioning it as the fourth respiratory vaccine in the pipeline achieving this milestone. Moreover, Moderna anticipates results from two additional Phase 3 studies in 2024, focusing on a combination flu and COVID-19 vaccine and a cytomegalovirus (CMV) vaccine.

In addition to these developments, Moderna shared positive clinical trial data from three new vaccines targeting the Epstein-Barr virus, Varicella-Zoster virus, and norovirus, all moving toward Phase 3 development. The company also expects to launch its respiratory syncytial virus (RSV) vaccine in the U.S. in 2024 pending FDA approval and ACIP recommendation. A significant funding agreement with Blackstone Life Sciences, worth up to $750 million, aims to further advance Moderna’s flu vaccine program.

The portfolio update, shared during Moderna’s fifth Vaccines Day event, underscores its extensive effort to tackle infectious diseases causing significant health burdens. With nine vaccines in Phase 3 trials or nearing this stage, Moderna’s CEO, Stéphane Bancel, expressed optimism about addressing unmet medical needs across a range of infectious diseases. The company’s pipeline includes 28 vaccines targeting various pathogens, with a promising outlook for several vaccine candidates progressing in clinical trials.